- Home
- PSBD vs CADL Comparison
PSBD vs CADL Comparison
Compare PSBD & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$5.30
Company Overview
Basic Information| Metric | PSBD | CADL |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.0M | 339.8M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSBD | CADL |
|---|---|---|
| Price | $12.26 | $5.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $13.30 | ★ $19.43 |
| AVG Volume (30 Days) | 78.1K | ★ 723.8K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | ★ 13.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.51 | $4.25 |
| 52 Week High | $16.16 | $14.60 |
Technical Indicators
Market Signals| Indicator | PSBD | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 58.58 |
| Support Level | $12.10 | $4.38 |
| Resistance Level | $12.45 | $4.87 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 75.36 | 93.81 |
Price Performance
Historical Comparison PSBD
CADL
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.